XNAS · Healthcare · Biotechnology
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2025-11-24 | Q3 2025 | -0.17 | 1.41 | +929.41% | $63.3M | ✅ Beat | — | — | — |
| 2025-08-15 | Q2 2025 | -0.18 | -0.36 | -100.00% | $16.4M | mixed | +0.00% | -0.73% | -2.19% |
| 2025-04-10 |
| Q4 2024 |
| -0.09 |
| -0.15 |
| -66.67% |
| $15.4M |
| ❌ Miss |
| +11.54% |
| +9.09% |
| +26.57% |
| 2024-08-15 | Q2 2024 | -0.29 | -0.32 | -10.34% | $8.2M | ❌ Miss | -0.31% | -1.85% | +0.62% |
| 2024-05-23 | Q1 2024 | -0.26 | -0.33 | -26.92% | $13.4M | ❌ Miss | -7.05% | -5.04% | -12.59% |
| 2024-04-24 | Q4 2023 | -0.20 | -0.41 | -105.00% | $24.5M | ❌ Miss | -7.97% | +5.58% | +47.01% |
| 2023-11-14 | Q3 2023 | -0.24 | -0.24 | +0.00% | $18.0M | ➖ Inline | -2.30% | -3.00% | +2.12% |
| 2023-08-17 | Q2 2023 | -0.26 | -0.34 | -30.77% | $22.0M | ❌ Miss | +3.01% | +1.62% | -10.29% |
Showing last 8 quarters.